Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,077,843

« Back to Dashboard
Patent 6,077,843 protects INVEGA TRINZA and INVEGA SUSTENNA and is included in two NDAs.

Protection for INVEGA TRINZA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-six patent family members in thirty-six countries.

Summary for Patent: 6,077,843

Title: Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
Abstract:The present invention is concerned with a pharmaceutical composition suitable as a depot formulation for administration via intramuscular or subcutaneous injection, comprising: (1) as an active ingredient a therapeutically effective amount of a 9-hydroxyrisperidone fatty acid ester or a salt, or a stereoisomer or a stereoisomeric mixture thereof and (2) a pharmaceutically acceptable carrier; wherein the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein; and with a process of preparing such a composition. The invention further concerns such a pharmaceutical composition for use as a medicament in the treatment of schizophrenia, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, bipolar mania, depression, anxiety.
Inventor(s): Fran.cedilla.ois; Marc Karel Jozef (Kalmthout, BE), Embrechts; Roger Carolus Augusta (Oud-Turnhout, BE), Borghijs; Herman Karel (Willebroek, BE), Monbaliu; Johan (Turnhout, BE)
Assignee: Janssen Pharmaceutica, N.V. (Beerse, BE)
Application Number:09/180,659
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Process; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 11th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Janssen Pharms
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-001May 18, 2015RXNo6,077,843*PEDNov 12, 2017Y
Janssen Pharms
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-002May 18, 2015RXNo6,077,843*PEDNov 12, 2017Y
Janssen Pharms
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207946-003May 18, 2015RXNo6,077,843*PEDNov 12, 2017Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,077,843

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
96 201 429May 20, 1996
PCT Information
PCT FiledMay 12, 1997PCT Application Number:PCT/EP97/02504
PCT Publication Date:November 27, 1997PCT Publication Number: WO97/44039

International Patent Family for Patent: 6,077,843

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Czech Republic291284<disabled in preview>
Germany69708284<disabled in preview>
Germany122011100027<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.